Molecular Profile Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Profile Name CD274 pos STK11 mut
Gene Variant Detail

CD274 positive (unknown)

STK11 mutant (unknown)

Relevant Treatment Approaches

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Relevant Treatment Approaches Therapy Name Approval Status Evidence Type Efficacy Evidence References
CD274 pos STK11 mut lung non-small cell carcinoma predicted - resistant unspecified PD-1 antibody Clinical Study - Cohort Actionable In a clinical study, non-small cell lung carcinoma patients positive for CD274 and harboring an STK11 mutation treated with a PD-1 inhibitor demonstrated a lower objective response rate compared to CD274-positive patients with wild-type STK11, 0% (0/11) vs 34.5% (19/55), respectively (PMID: 29773717). 29773717
CD274 pos STK11 mut lung non-small cell carcinoma not predictive Pembrolizumab Clinical Study Actionable In a retrospective analysis of a Phase III trial (KEYNOTE-042), Keytruda (pembrolizumab) treatment resulted in a similar improved overall survival compared to chemotherapy in patients with CD274 (PD-L1)-positive non-small cell lung cancer with either an STK11 mutation (HR=0.37) or wild-type STK11 (HR=0.83) (PMID: 36709038; NCT02220894). 36709038